{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:56:27Z","timestamp":1793350587084,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Janssen and Gandel Philanthropy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The optimal infliximab (IFX) dosing strategy for acute severe ulcerative colitis (ASUC) remains unclear. Though intensified IFX dosing is frequently employed, evidence supporting its efficacy has been mixed and it is uncertain if intensified IFX more effectively captures remission than standard-dose IFX. We conducted an updated meta-analysis comparing standard- vs intensified-dose IFX in ASUC, incorporating PREDICT-UC trial data and applying a Bayesian framework to better integrate prior evidence and quantify uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Electronic databases were systematically searched from inception to December 2024 (PROSPERO ID: CRD42024616359). We conducted a 2-step meta-analysis. First, retrospective cohort studies were assessed with a frequentist random-effects meta-analytic approach. Second, because there is only 1 trial (PREDICT-UC) comparing intensified vs standard IFX in ASUC, we applied a Bayesian meta-analytic approach by using historical trials of standard-dose IFX in ASUC to define the prior probability distribution and then compared that to PREDICT-UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten retrospective cohort studies (530 standard-dose and 406 intensified-dose patients) were included in the frequentist analysis. We applied a Bayesian binomial regression model with the historical randomized controlled trials of standard-dose IFX as the reference group. The estimated 3-month colectomy rate for standard-dose IFX was 27% (95% credible interval, 22%-33%). In the PREDICT-UC trial, observed colectomy rates were 15% in patients receiving rescue-dose IFX at 5\u2009mg\/kg and 6% in those receiving upfront intensified dosing at 10\u2009mg\/kg. Posterior estimates for both intensified dosing strategies in PREDICT-UC were credibly lower than the standard-dose IFX reference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integrating observational and trial data via Bayesian methods suggests that intensified IFX dosing reduces early colectomy in ASUC. These findings support prospective, adequately powered trials to confirm benefit, identify subgroups most likely to respond, and refine individualized accelerated-dosing algorithms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag042","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:47:14Z","timestamp":1772628434000},"page":"1344-1353","source":"Crossref","is-referenced-by-count":3,"title":["Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis"],"prefix":"10.1093","volume":"32","author":[{"given":"Manjeet K","family":"Goyal","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, All India Institute of Medical Sciences , New Delhi, 110029,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyata","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Trinity Health, St. Joseph Mercy Ann Arbor , Ann Arbor, MI 48197,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5206-0097","authenticated-orcid":false,"given":"Matthew C","family":"Choy","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Austin Health , Melbourne, Victoria, 3084,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne, Austin Health , Melbourne, Victoria, 3084,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Berinstein","sequence":"additional","affiliation":[{"name":"Divison of Gastroenterology and Hepatology, University of Michigan , Ann Arbor, MI, 48109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A","family":"Hassan","sequence":"additional","affiliation":[{"name":"Divison of Gastroenterology and Hepatology, University of Michigan , Ann Arbor, MI, 48109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-3409","authenticated-orcid":false,"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Postgraduate Institute of Medical Education and Research , Chandigarh, 160012,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1577-0118","authenticated-orcid":false,"given":"Vineet","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, All India Institute of Medical Sciences , New Delhi, 110029,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Berinstein","sequence":"additional","affiliation":[{"name":"Divison of Gastroenterology and Hepatology, University of Michigan , Ann Arbor, MI, 48109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4095-1153","authenticated-orcid":false,"given":"Christopher F D","family":"Li Wai Suen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Austin Health , Melbourne, Victoria, 3084,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne, Austin Health , Melbourne, Victoria, 3084,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D R","family":"Higgins","sequence":"additional","affiliation":[{"name":"Divison of Gastroenterology and Hepatology, University of Michigan , Ann Arbor, MI, 48109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4983-6103","authenticated-orcid":false,"given":"Danny","family":"Con","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Austin Health , Melbourne, Victoria, 3084,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne, Austin Health , Melbourne, Victoria, 3084,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter De","family":"Cruz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Austin Health , Melbourne, Victoria, 3084,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne, Austin Health , Melbourne, Victoria, 3084,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4823-5805","authenticated-orcid":false,"given":"Shrinivas","family":"Bishu","sequence":"additional","affiliation":[{"name":"Divison of Gastroenterology and Hepatology, University of Michigan , Ann Arbor, MI, 48109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"2026070620114215700_izag042-B1","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019","edition":"2nd ed."},{"key":"2026070620114215700_izag042-B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5009\/gnl220017","article-title":"Acute severe ulcerative colitis: optimal strategies for drug therapy","volume":"17","author":"Nakase","year":"2023","journal-title":"Gut Liver"},{"key":"2026070620114215700_izag042-B3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070620114215700_izag042-B4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10928-019-09652-5","article-title":"Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients","volume":"46","author":"Berends","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026070620114215700_izag042-B5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620114215700_izag042-B6","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"J\u00e4rnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"2026070620114215700_izag042-B7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","article-title":"Acute severe ulcerative colitis management: unanswered questions and latest insights","volume":"9","author":"Rivi\u00e8re","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070620114215700_izag042-B8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5217\/ir.2024.00003","article-title":"What to do when traditional rescue therapies fail in acute severe ulcerative colitis","volume":"22","author":"Suen","year":"2024","journal-title":"Intest Res"},{"key":"2026070620114215700_izag042-B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070620114215700_izag042-B10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070620114215700_izag042-B11","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"2026070620114215700_izag042-B12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026070620114215700_izag042-B13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026070620114215700_izag042-B14","doi-asserted-by":"publisher","first-page":"goae051","DOI":"10.1093\/gastro\/goae051","article-title":"Comparison of accelerated and standard infliximab induction regimens in acute severe ulcerative colitis using propensity score analysis: a retrospective multicenter study in China","volume":"12","author":"Liu","year":"2024","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2026070620114215700_izag042-B15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.cgh.2018.06.031","article-title":"Effect of accelerated infliximab induction on short- and long-term outcomes of acute severe ulcerative colitis: a retrospective multi-center study meta-analysis","volume":"17","author":"Nalagatla","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070620114215700_izag042-B16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","article-title":"Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial","volume":"9","author":"Choy","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070620114215700_izag042-B17","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026070620114215700_izag042-B18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume-title":"BMJ","author":"Sterne","year":"2019"},{"key":"2026070620114215700_izag042-B19","doi-asserted-by":"publisher","first-page":"S382","DOI":"10.14309\/00000434-201710001-00692","article-title":"Accelerated dosing of infliximab is not associated with improved colectomy rates in hospitalized severe ulcerative colitis patients: 692","volume":"112","author":"Sly","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2026070620114215700_izag042-B20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/ibd\/izx039","article-title":"Accelerated infliximab dosing increases 30-day colectomy in hospitalized ulcerative colitis patients: a propensity score analysis","volume":"24","author":"Shah","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026070620114215700_izag042-B21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s10620-018-5358-z","article-title":"High-dose infliximab rescue therapy for hospitalized acute severe ulcerative colitis does not improve colectomy-free survival","volume":"64","author":"Chao","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2026070620114215700_izag042-B22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/apt.15456","article-title":"Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis","volume":"50","author":"Sebastian","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620114215700_izag042-B23","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1007\/s10620-020-06071-2","article-title":"Prevalence and effect of intestinal infections detected by a PCR-based stool test in patients with inflammatory bowel disease","volume":"65","author":"Limsrivilai","year":"2020","journal-title":"Dig Dis Sci"},{"key":"2026070620114215700_izag042-B24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/jgh.15271","article-title":"Standard (5 mg\/kg) versus intensified (10 mg\/kg) infliximab dosing in patients with acute severe ulcerative colitis: a 4-year retrospective study","volume":"35","author":"Yogakanthi","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"2026070620114215700_izag042-B25","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1097\/DCR.0000000000002176","article-title":"Dose-intensified infliximab rescue therapy for severe ulcerative colitis does not reduce short-term colectomy rates or increase postoperative complications","volume":"65","author":"Kosaraju","year":"2022","journal-title":"Dis Colon Rectum"},{"key":"2026070620114215700_izag042-B26","doi-asserted-by":"publisher","first-page":"S-1131","DOI":"10.1016\/S0016-5085(23)03609-0","article-title":"Tu1794 accelerated infliximab induction for patients hospitalized with acute ulcerative colitis is associated with reduced risk of long-term colectomy compared to standard induction","volume":"164","author":"Nattakom","year":"2023","journal-title":"Gastroenterology"},{"key":"2026070620114215700_izag042-B27","doi-asserted-by":"publisher","first-page":"156407","DOI":"10.1155\/2011\/156407","article-title":"Short-and long-term clinical outcomes of infliximab in fulminant ulcerative colitis","volume":"2011","author":"Florholmen","year":"2011","journal-title":"Ulcers"},{"key":"2026070620114215700_izag042-B28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/gutjnl-2016-313060","article-title":"Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab","volume":"67","author":"Laharie","year":"2018","journal-title":"Gut"},{"key":"2026070620114215700_izag042-B29","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.dld.2025.10.026","article-title":"Comparative efficacy of immunomodulators, biologics, and advanced therapies for steroid-refractory acute severe ulcerative colitis: a network meta-analysis and time-to-event analysis","volume":"57","author":"Hayek","year":"2025","journal-title":"Dig Liver Dis"},{"key":"2026070620114215700_izag042-B30","doi-asserted-by":"publisher","first-page":"i251","DOI":"10.1093\/ecco-jcc\/jjae190.0130","article-title":"DOP091 Early serum infliximab levels predict outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UC","volume":"19","author":"Li Wai Suen","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026070620114215700_izag042-B31","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/apt.13631","article-title":"Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis","volume":"43","author":"Ungar","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026070620114215700_izag042-B32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"2026070620114215700_izag042-B33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"2026070620114215700_izag042-B34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cgh.2015.10.029","article-title":"Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis","volume":"14","author":"Brandse","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026070620114215700_izag042-B35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/ecco-jcc\/jjx146","article-title":"Exploration of predictive biomarkers of early infliximab response in acute severe colitis: a prospective pilot study","volume":"12","author":"Beswick","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026070620114215700_izag042-B36","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/pharmaceutics13111821","article-title":"Infliximab efficacy may be linked to full TNF-\u03b1 blockade in peripheral compartment-A double central-peripheral target-mediated drug disposition (TMDD) model","volume":"13","author":"Ternant","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026070620114215700_izag042-B37","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.3390\/jcm12103378","article-title":"Therapeutic drug monitoring of infliximab in acute severe ulcerative colitis","volume":"12","author":"Gordon","year":"2023","journal-title":"J Clin Med"},{"key":"2026070620114215700_izag042-B38","doi-asserted-by":"publisher","first-page":"jjaf021","DOI":"10.1093\/ecco-jcc\/jjaf021","article-title":"Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review","volume":"19","author":"Gisbert","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026070620114215700_izag042-B39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"2026070620114215700_izag042-B40","doi-asserted-by":"publisher","first-page":"17562848251323511","DOI":"10.1177\/17562848251323511","article-title":"Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series","volume":"18","author":"Etchegaray","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"2026070620114215700_izag042-B41","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s10620-019-05957-0","article-title":"Use of Accelerated Induction Strategy of Infliximab for Ulcerative Colitis in Hospitalized Patients at a Tertiary Care Center","volume":"65","year":"2020","journal-title":"Dig Dis Sci"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/7\/1344\/68155944\/izag042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/7\/1344\/68155944\/izag042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:11:47Z","timestamp":1783383107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/7\/1344\/8662089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4,24]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag042","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,24]]}}}